Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 4;13:2201–2213. doi: 10.2147/CMAR.S288111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Lu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

TRIM56 DNA copy number alteration (CNA), mutation and methylation in LUAD. (A) Genetic alteration of TRIM56 in 816 cases of LUAD via cBioportal. (B) Heatmap of TRIM56 mRNA expression, copy number alteration and DNA methylation in patients with primary LUAD. −2: Homozygous deletion; −1: Heterozygous loss, 0: Copy neutral; +1: Low-level copy gain; +2: High-level amplification. Data from GDC TCGA Lung Adenocarcinoma (LUAD) of UCSC (C) Plot chart showing TRIM56 expression in LUAD tissues with copy-number alteration. *P<0.05. (D) Scatter plot showing mutation alteration of TRIM56 in LUAD patients via cBioPortal. ns, no significance. (E) Regression analysis of TRIM56 DNA methylation and TRIM56 expression. (F) Boxplot showing Promoter methylation of TRIM56 from LUAD patients via UALCAN. *P<0.05.